INTRODUCTION {#s1}
============

Cancer has to be the second-leading cause in 2015 that caused over 8.8 million deaths worldwide in 2015 \[[@R1]\]. Due to countries geographical environment, living habits, cancer incidence is very different. The incidence of cancer in developing countries such as Africa, Asia and South America is the most severe. A total of 14 million cancer cases were added worldwide and 8.2 million people died in 2012. Among them, China added 3.07 million cancer patients and caused about 2.2 million deaths, accounting for 21.9% of the total global deaths. The incidence of cancer in developed countries is still higher than in developing countries. Residents of North America and Europe are the most vulnerable to cancer, but China has a large population base, making it the country with the highest number of cancer deaths throughout the world. As more and more people in developing countries improve their living standards and dietary patterns change, the chances of cancer have increased significantly in developing countries \[[@R2]\]. The etiology of cancer involves both genetic and environmental factors. Therefore, understanding the impact of environmental factors on cancer will help to prevent cancer.

Oral cavity is an important part of the body, and is starts in the digestive system, mainly by the lip and cheek, tongue and palate, salivary glands, teeth and jaw, with mastication, swallowing, speech and feeling, and other functions, which maintain the normal shape of maxillofacial. Oral health is an important part of human health. The World Health Organization (WHO) identifies dental health as one of the top ten criteria for human health. Poor oral health may increase systemic inflammation, resulting in a local overly aggressive immune response, and thus could have important implications for cancer development. Periodontal disease and tooth loss are two common oral health measures \[[@R3]\]. Tooth loss has been considered to impact quality of life \[[@R4]\], and been known to considerably influence food choice, diet, nutrition intake, and esthetics \[[@R5]\].

Previous studies have examined the correlation between tooth loss and cancer risk \[[@R6]--[@R30]\]. However, the result remains controversial. Additionally, no study to quantitative assessed tooth loss in relation to cancer risk. Thus, we performed this dose-response meta-analysis to clarify and quantitative assessed the correlation between tooth loss and cancer risk.

MATERIALS AND METHODS {#s2}
=====================

This meta-analysis was conducted according to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) checklist \[[@R31]\].

Search strategy {#s2_1}
---------------

We included eligible studies to investigate the relationship between tooth loss and cancer risk in general adult populations. To develop a flexible, non-linear, r meta-regression model, we required that an eligible study should have categorized into 3 or more levels.

PubMed and EMBASE were searched for studies that contained risk estimates for the outcomes of cancer and were published update to March 2017, with keywords including "dentition" \[MeSH\] OR "tooth loss" \[MeSH\] OR "edentulous" \[MeSH\] OR "lost of tooth" \[MeSH\] AND "cancer" \[MeSH\] OR "tumor" \[MeSH\] OR "neoplasms" \[MeSH\]. We refer to the relevant original essays and commentary articles to determine further relevant research.

Study selection {#s2_2}
---------------

Two independent researchers investigate information the correlation between tooth loss and cancer risk: outcome was cancer. Moreover, we precluded non-human studies, reviews, meta-analyses, editorials and published letters.

Data extraction {#s2_3}
---------------

Use standardized data collection tables to extract data. Each eligible article information was extracted by two independent researchers. We extracted the following information: first author; publication year; age; country; sex; cases and participants; the categories of tooth loss; relative risk or odds ratio (OR). We collect the risk estimates with multivariable-adjusted \[[@R32]\]. According to the Newcastle-Ottawa scale, quality assessment was performed for non-randomized studies \[[@R33]\]. The disagreements were resolved through consensus by all the authors.

Statistical analysis {#s2_4}
--------------------

We pooled relative risk estimates to measure the association between tooth loss and cancer; the hazard ratio were considered equivalent to the relative risk \[[@R34]\]. Results in different subgroups of tooth loss and cancer risk were treated as two separate reports.

Due to different definitions cut-off points in the included studies for categories, we performed a relative risk estimates by the method recommended by Greenland, Longnecker and Orsini and colleagues \[[@R35]\]. Dose of tooth loss used the median tooth loss. If the median tooth loss category was not available, the midpoint of the upper and lower boundaries was considered the dose of each category. In addition, using restricted cubic splines to evaluate the non-linear association between tooth loss and cancer risk, with three knots at the 10th, 50th, and 90th percentiles of the distribution. A flexible meta-regression based on restricted cubic spline (RCS) function was used to fit the potential non-linear trend, and generalized least-square method was used to estimate the parameters. This procedure treats tooth loss (continuous data) as an independent variable and logRR of diseases as a dependent variable, with both tails of the curve restricted to linear. A *P* value is calculated for linear or non-linear by testing the null hypothesis that the coefficient of the second spline is equal to zero \[[@R32]\].

The between-study heterogeneity was assessed by *Q*-statistic (signifcance level at *P* ≤ 0.10) and the I^2^-statistic. STATA software 14.0 (STATA Corp, College Station, TX, USA) was using in all analyses. *P* \< 0.05 was considered signifcant for all tests.

RESULTS {#s3}
=======

Literature search results {#s3_1}
-------------------------

We identifed 3088 relevant citations after removing duplicates. Reviewing their titles and abstracts, 3021 citations were excluded. The remaining 67 citations were assessed in more detail for eligibility by reading the full text. Among them, 43 were excluded, after review reference, one articles was included. Finally, 25 studies were used for the final data synthesis \[[@R6]--[@R30]\]. The flow chart of literature searching was presented in Figure [1](#F1){ref-type="fig"}, and the data were extracted. These studies were published update to March 2017.

![Flow diagram of the study selection process](oncotarget-09-15090-g001){#F1}

Study characteristics {#s3_2}
---------------------

The characteristics of the included studies of tooth loss and cancer risk are shown in the Table [1](#T1){ref-type="table"} and [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Among the selected studies, nine focused on esophageal cancer \[[@R6]--[@R13], [@R24]\], five focused on gastric cancer \[[@R6], [@R7], [@R12], [@R13], [@R15]\], eleven focused on head and neck cancer \[[@R11]--[@R13], [@R16]--[@R20], [@R23], [@R25], [@R26]\], four focused on colorectal cancer \[[@R12], [@R13], [@R28], [@R29]\], five focused on pancreas cancer \[[@R12]--[@R14], [@R21], [@R30]\], two focused on lung cancer \[[@R12], [@R13]\], two focused on prostate cancer \[[@R12], [@R13]\] and two focused on bladder cancer \[[@R12], [@R13]\]. Results in different subgroups were treated as two separate reports. Finally, Eighty-one independent reports from twenty five studies investigated the association between tooth loss and cancer.

###### Characteristics of participants in included studies of tooth loss in relation to risk of cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                       Study design   Country          Sex of population   Age at baseline (years)   No of participants   Endpoints (cases)                                                 Quality score
  ----------------------------------- -------------- ---------------- ------------------- ------------------------- -------------------- ----------------------------------------------------------------- ---------------
  Abnet et al. (2001)                 cohort         China            Mix                 40--69                    29548                Esophageal cancer (620)\                                          8
                                                                                                                                         Gastric cancer (533)                                              

  Abnet et al. (2005)                 cohort         Finnish          Mix                 50--69                    29124                Esophageal cancer (49)\                                           8
                                                                                                                                         Gastric cancer (245)                                              

  Abnet et al. (2008)                 case-control   Iran             Mix                 \> 18                     843                  Esophageal cancer (283)                                           6

  Dar et al. (2013)                   case-control   Kashmir          Mix                 61.6                      2367                 Esophageal cancer (703)                                           6

  Dye et al. (2007)                   case-control   China            Mix                 40--67                    977500               Esophageal cancer (579)                                           6

  Guha et al. (2007)                  case-control   USA and Europe   Mix                 any age                   Europe (4110)\       Europe:\                                                          7
                                                                                                                    USA (1852)           Esophageal cancer (91)\                                           
                                                                                                                                         Head and neck cancer (507)\                                       
                                                                                                                                         USA\                                                              
                                                                                                                                         Esophageal cancer (95)\                                           
                                                                                                                                         Head and neck cancer (1457)                                       

  Hiraki et al. (2008)                case-control   Japan            Mix                 58.0                      15720                Head and neck (429)\                                              7
                                                                                                                                         Esophagus (354)\                                                  
                                                                                                                                         Stomach (702)\                                                    
                                                                                                                                         Colon (662)\                                                      
                                                                                                                                         Liver (167)\                                                      
                                                                                                                                         Pancreas (178)\                                                   
                                                                                                                                         Lung (909)\                                                       
                                                                                                                                         Breast (756)\                                                     
                                                                                                                                         Uterus (429)\                                                     
                                                                                                                                         Ovary (103)\                                                      
                                                                                                                                         Prostate (136)\                                                   
                                                                                                                                         Bladder (62)\                                                     
                                                                                                                                         Thyroid (121)\                                                    
                                                                                                                                         Lymphoma (232)                                                    

  Michaud et al. (2008)               cohort         USA              Male                40--75                    48375                Total (5720)\                                                     8
                                                                                                                                         Lung (678)\                                                       
                                                                                                                                         Oropharyngeal (118)\                                              
                                                                                                                                         Esophageal (131)\                                                 
                                                                                                                                         Stomach (106)\                                                    
                                                                                                                                         Pancreatic (253)\                                                 
                                                                                                                                         Colorectal (1043)\                                                
                                                                                                                                         Kidney (271)\                                                     
                                                                                                                                         Lung (678)\                                                       
                                                                                                                                         Bladder (543)\                                                    
                                                                                                                                         Prostate (541)\                                                   
                                                                                                                                         Hematopoietic (934)\                                              
                                                                                                                                         Brain (132)\                                                      
                                                                                                                                         Skin Melanoma (698)\                                              
                                                                                                                                         Non-Hodgkin lymphoma (524)\                                       
                                                                                                                                         Leukemia (250)\                                                   
                                                                                                                                         Multiple myeloma (141)                                            

  Michaud et al. (2007)               cohort         USA              Male                40--75                    51529                Pancreatic (216)                                                  8

  Shakeri et al. (2013)               case-control   Iran             Mix                 40--75                    922                  Gastric (588)                                                     6

  Balaram et al. (2002)               case-control   India            Mix                 22--58                    1164                 oral cavity (584)                                                 5

  Bundgaard et al. (1995)             case-control   Denmark          Mix                 \< 75                     559                  oral cavity (161)                                                 6

  Garrote et al. (2001)               case-control   Cuba             Mix                 60                        400                  oral cavity (200)                                                 5

  Lissowska et al. (2003)             case-control   Poland           Mix                 23--80                    244                  oral cancer (122)                                                 6

  Talamini et al. (2000)              case-control   Italian          Mix                 27--86                    274                  oral cancer (131)                                                 6

  Stolzenberg-Solomon et al. (2003)   cohort         Finland          Male                50--69                    29104                pancreatic cancer (174)                                           8

  Bertrand et al. (2017)              cohort         USA              Male                40--75                    51529                NonHodgkin lymphoma (875)\                                        8
                                                                                                                                         Chronic lymphocytic leukemia/small lymphocytic lymphomas (290)\   
                                                                                                                                         diffuse large B-cell lymphomas (85)\                              
                                                                                                                                         Follicular lymphomas (91)                                         

  Chen et al. (2016)                  case-control   China            Female              20--80                    1246                 Oral cancer (250)                                                 6

  Chen et al. (2016)                  case-control   China            Mix                 40--85                    1386                 Esophagus (616)                                                   6

  Zuo et al. (2014)                   case-control   China            Mix                 \> 18                     317                  Oral cancer (150)                                                 7

  Divaris et al. (2010)               case-control   USA              Mix                 26--80                    2650                 Head and Neck Cancer (1361)                                       6

  Liu et al. (2016)                   case-control   China            Mix                 20--74                    5124                 nasopharyngeal carcinoma (2528)                                   6

  Momen-Heravi et al. (2017)          cohort         USA              Female              39--55                    77443                colorectal cancer (1165)                                          8

  Ren et al. (2016)                   case-control   China            Mix                 40--79                    6619                 colorectal cancer (1063)                                          6

  Huang et al. (2016)                 cohort         Sweden           Mix                 20--70                    19924                pancreatic cancer (126)                                           8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Tooth loss and overall cancer risk {#s3_3}
----------------------------------

Eighty-one independent reports from twenty five studies investigated the association between tooth loss and cancer \[[@R6]--[@R30]\]. Compared with the lowest tooth loss, tooth loss is significantly associated with a higher risk of cancer risk (RR:1.06; 95% CI, 1.02--1.09; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 9% incremental in cancer risk (RR: 1.09; 95% CI, 1.05--1.13) (Figure [2](#F2){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and cancer (*P* \< 0.001 for non-linearity; Figure [2](#F2){ref-type="fig"}).

###### Stratified analyses of relative risk of cancer

                                               No of reports   Relative risk (95% CI)   P for heterogeneity   I^2^    P for test
  -------------------------------------------- --------------- ------------------------ --------------------- ------- ------------
  Total                                        81              1.06 (1.02--1.09)        0.000                 51.2%   \< 0.001
  Subgroup analyses for cancer                                                                                        
  Esophageal cancer                            10              1.18 (1.04--1.31)        0.558                 0.0%    \< 0.001
  Subgroup analyses for Esophageal cancer                                                                             
  Study location                                                                                                      
  Caucasia                                     6               1.12 (1.02--1.21)        0.520                 0.0%    \< 0.001
  Asia                                         4               1.26 (1.08--1.44)        0.363                 5.9%    \< 0.001
  Study design                                                                                                        
  Case--control                                7               1.34 (1.04--1.64)        0.736                 0.0%    \< 0.001
  Cohort                                       3               1.11 (1.04--1.18)        0.460                 0.0%    \< 0.001
  Study quality                                                                                                       
  Score ≥ 7                                    3               1.11 (1.04--1.18)        0.460                 0.0%    \< 0.001
  Score \< 7                                   7               1.34 (1.04--1.64)        0.736                 0.0%    \< 0.001
  Gastric cancer                               9               1.09 (1.03--1.16)        0.763                 0.0%    \< 0.001
  Subgroup analyses for Gastric cancer                                                                                
  Study location                                                                                                      
  Caucasia                                     6               1.25 (1.11--1.36)        0.737                 0.0%    \< 0.001
  Asia                                         3               1.04 (1.01--1.09)        0.863                 0.0%    \< 0.001
  Study design                                                                                                        
  Case--control                                4               1.10 (1.02--1.19)        0.739                 0.0%    \< 0.001
  Cohort                                       5               1.13 (1.04--1.23)        0.474                 0.0%    \< 0.001
  Study quality                                                                                                       
  Score ≥ 7                                    5               1.13 (1.04--1.23)        0.474                 0.0%    \< 0.001
  Score \< 7                                   4               1.10 (1.02--1.19)        0.739                 0.0%    \< 0.001
  Head and neck cancer                         19              1.52 (1.14--1.90)        0.000                 71.3%   \< 0.001
  Subgroup analyses for Head and neck cancer                                                                          
  Oral cancer                                  15              1.80 (1.30--2.30)        0.000                 67.7%   \< 0.001
  Pharynx                                      2               1.14 (1.05--1.23)        0.295                 5.7%    \< 0.001
  Larynx cancer                                2               1.08 (1.02--1.15)        0.004                 87.5%   \< 0.001
  Study location                                                                                                      
  Caucasia                                     11              1.15 (1.04--1.26)        0.004                 61.2%   \< 0.001
  Asia                                         8               1.82 (1.52--2.12)        0.288                 18.6%   \< 0.001
  Study design                                                                                                        
  Case--control                                18              1.52 (1.13--1.92)        0.000                 72.7%   \< 0.001
  Cohort                                       1               1.60 (0.84--3.04)        0.288                 18.6%   0.121
  Study quality                                                                                                       
  Score ≥ 7                                    9               1.13 (1.04--1.23)        0.001                 70.1%   \< 0.001
  Score \< 7                                   10              1.91 (1.58--2.24)        0.171                 29.8%   \< 0.001
  Colorectal cancer                            13              1.07 (1.02--1.14)        0.114                 33.5%   \< 0.001
  Subgroup analyses for Colorectal cancer                                                                             
  Colon                                        5               1.09 (1.02--1.17)        0.330                 13.2%   \< 0.001
  Rectal                                       3               1.08 (1.01--1.17)        0.082                 60.0%   \< 0.001
  Study location                                                                                                      
  Caucasia                                     6               1.17 (1.07--1.27)        0.692                 0.0%    \< 0.001
  Asia                                         7               1.05 (1.01--1.09)        0.986                 0.0%    \< 0.001
  Study design                                                                                                        
  Case--control                                7               1.05 (1.01--1.09)        0.986                 0.0%    \< 0.001
  Cohort                                       6               1.17 (1.07--1.27)        0.692                 0.0%    \< 0.001
  Study quality                                                                                                       
  Score ≥ 7                                    7               1.16 (1.06--1.25)        0.669                 0.0%    \< 0.001
  Score \< 7                                   6               0.84 (0.65--1.03)        0.970                 0.0%    0.316
  Pancreas cancer                              5               1.15 (1.05--1.19)        0.498                 0.0%    \< 0.001
  Lung cancer                                  2               1.66 (1.34--1.97)        0.660                 0.0%    \< 0.001
  Prostate cancer                              2               1.14 (1.03--1.25)        0.481                 0.0%    \< 0.001
  Bladder cancer                               2               1.23 (1.12--1.35)        0.596                 0.0%    \< 0.001
  Hematopoietic cancer                         9               1.07 (1.02--1.13)        0.443                 0.0%    \< 0.001

![Dose-response relationship between tooth loss in relation to risk of overall cancer](oncotarget-09-15090-g002){#F2}

Tooth loss and esophageal cancer {#s3_4}
--------------------------------

Ten independent reports from nine studies investigated the association between tooth loss and esophageal cancer \[[@R6]--[@R13], [@R24]\]. Compared with the lowest tooth loss, tooth loss is significantly associated with a higher risk of esophageal cancer (RR:1.18; 95% CI, 1.04--1.31; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Furthermore, tooth loss is significantly associated with esophageal cancer risk in Caucasia (RR:1.12; 95% CI, 1.02--1.21; *P* \< .001) (Table [2](#T2){ref-type="table"}) and Asia (RR:1.26; 95% CI, 1.08--1.44; *P* \< .001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 14% incremental in esophageal cancer risk (RR: 1.14; 95% CI, 1.05--1.25) (Figure [3](#F3){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and esophageal cancer (*P* \< 0.001 for non-linearity; Figure [3](#F3){ref-type="fig"}).

![Dose-response relationship between tooth loss in relation to risk of cancer\
(**A**) Colorectal cancer. (**B**) Esophageal cancer. (**C**) Gastric cancer. (**D**) Head and neck cancer.](oncotarget-09-15090-g003){#F3}

Tooth loss and gastric cancer {#s3_5}
-----------------------------

Nine independent reports from five studies investigated the association between tooth loss and gastric cancer \[[@R6], [@R7], [@R12], [@R13], [@R15]\]. The results of tooth loss and gastric cancer risk are shown in Table [2](#T2){ref-type="table"}. Compared with lowest the tooth loss, tooth loss is significantly associated with a higher risk of gastric cancer (RR: 1.09; 95% CI, 1.03--1.16; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Furthermore, tooth loss is significantly associated with gastric cancer risk in Caucasia (RR:1.25; 95% CI, 1.11--1.36; *P* \< 0.001) (Table [2](#T2){ref-type="table"}) and Asia (RR:1.04; 95% CI, 1.01--1.09; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 9% incremental in gastric cancer risk (RR: 1.09; 95% CI, 1.01--1.18; *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and gastric cancer (*P* \< 0.001 for non-linearity; Figure [3](#F3){ref-type="fig"}).

Tooth loss and head and neck cancer {#s3_6}
-----------------------------------

Nineteen independent reports from eleven studies investigated the association between tooth loss and head and neck cancer \[[@R11]--[@R13], [@R16]--[@R20], [@R23], [@R25], [@R26]\]. Compared with the lowest tooth loss, tooth loss is significantly associated with head and neck cancer risk (RR:1.52; 95% CI, 1.14--1.90; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Furthermore, tooth loss is significantly associated with a higher risk of head and neck cancer in Caucasia (RR:1.15; 95% CI, 1.04--1.26; *P* \< 0.001) (Table [2](#T2){ref-type="table"}) and Asia (RR:1.82; 95% CI, 1.52--2.12; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Also, tooth loss is significantly associated with oral cancer (RR:1.80; 95% CI, 1.30--2.30; *P* \< 0.001) (Table [2](#T2){ref-type="table"}), Pharynx cancer (RR:1.14; 95% CI, 1.05--1.23; *P* \< 0.001) (Table [2](#T2){ref-type="table"}) and Larynx cancer (RR:1.08; 95% CI, 1.02--1.15; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 31% incremental in head and neck cancer risk (RR: 1.31; 95% CI, 1.15--1.50; *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and head and neck cancer cancer (*P* \< 0.001 for non-linearity; Figure [3](#F3){ref-type="fig"}).

Tooth loss and colorectal cancer {#s3_7}
--------------------------------

Thirteen independent reports from four studies investigated the association between tooth loss and colorectal cancer \[[@R12], [@R13], [@R28], [@R29]\]. Compared with the lowest tooth loss, tooth loss is significantly associated with a higher risk of colorectal cancer (RR:1.07; 95% CI, 1.02--1.14; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Furthermore, tooth loss is significantly associated with colorectal cancer risk in Caucasia (RR:1.17; 95% CI, 1.07--1.27; *P* \< 0.001) (Table [2](#T2){ref-type="table"}) and Asia (RR:1.05; 95% CI, 1.01--1.09; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Also, tooth loss is significantly associated with a higher risk of colon cancer (RR: 1.09; 95% CI, 1.02--1.17; *P* \< 0.001) (Table [2](#T2){ref-type="table"}) and rectal cancer (RR:1.08; 95% CI, 1.01--1.17; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 4% incremental in colorectal cancer risk (RR:1.04; 95% CI, 1.01--1.08; *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and colorectal cancer (*P* \< 0.001 for non-linearity; Figure [3](#F3){ref-type="fig"}).

Tooth loss and pancreas cancer {#s3_8}
------------------------------

Five independent reports from five studies investigated the association between tooth loss and pancreas cancer \[[@R12]--[@R14], [@R21], [@R30]\]. Compared with the lowest tooth loss, tooth loss is significantly associated with a higher risk of pancreas cancer (RR:1.15; 95% CI, 1.05--1.19; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 7% incremental in pancreas cancer risk (RR:1.07; 95% CI, 1.01--1.15; *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and pancreas cancer (*P* \< 0.001 for non-linearity; Figure [4](#F4){ref-type="fig"}).

![Dose-response relationship between tooth loss in relation to risk of cancer\
(**A**) Bladder cancer. (**B**) Hematopoietic cancer. (**C**) Lung cancer. (**D**) Pancreas cancer.](oncotarget-09-15090-g004){#F4}

Tooth loss and lung cancer {#s3_9}
--------------------------

Five independent reports from two studies investigated the association between tooth loss and lung cancer \[[@R12], [@R13]\]. Compared with lowest tooth loss, tooth loss is significantly associated with a higher risk of lung cancer (RR: 1.66; 95% CI, 1.34-1.97; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 19% incremental in lung cancer risk (RR:1.19; 95% CI, 1.04--1.35; *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and lung cancer (*P* \< 0.001 for non-linearity; Figure [4](#F4){ref-type="fig"}).

Tooth loss and bladder cancer {#s3_10}
-----------------------------

Two independent reports from two studies investigated the association between tooth loss and bladder cancer \[[@R12], [@R13]\]. Compared with lowest tooth loss, tooth loss is significantly associated with a higher risk of bladder cancer (RR: 1.23; 95% CI, 1.12--1.35; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 2% incremental in bladder cancer risk (RR: 1.02; 95% CI, 1.01--1.03; *P \<* 0.001) (Figure [4](#F4){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and bladder cancer (*P* \< 0.001 for non-linearity; Figure [4](#F4){ref-type="fig"}).

Tooth loss and hematopoietic cancer {#s3_11}
-----------------------------------

Two independent reports from two studies investigated the association between tooth loss and hematopoietic cancer \[[@R12], [@R13]\]. Compared with the lowest tooth loss, tooth loss is significantly associated with a higher risk of hematopoietic cancer (RR: 1.07; 95% CI, 1.02--1.13; *P* \< 0.001) (Table [2](#T2){ref-type="table"}). Additionally, a dose-response analysis revealed that each 10 tooth loss was associated with a 3% incremental in hematopoietic cancer risk (RR: 1.03; 95% CI, 1.01--1.07; *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). A cubic spline model revealed an positive non-linear correlation between tooth loss and hematopoietic cancer (*P* \< 0.001 for non-linearity; Figure [4](#F4){ref-type="fig"}).

Subgroup analyses {#s3_12}
-----------------

Subgroup analysis was performed to check the stability of the primary outcome. Subgroup meta-analyses in study design and study quality showed consistent findings (Table [2](#T2){ref-type="table"}).

Sensitivity analysis {#s3_13}
--------------------

Sensitivity analysis was conducted to assess the stability of the results. The results show the results were stable in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

Publication bias {#s3_14}
----------------

Each studies in this meta-analysis were performed to evaluate the publication bias by both Begg's funnel plot and Egger's test. *P* \> 0.05 was considered no publication bias. The results show no obvious evidence of publication bias was found in the associations between tooth loss and cancer risk ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s4}
==========

Cancer affects millions of people in developed and developing countries that is now a public health crisis. Despite the decline in the mortality rate of developed countries, cancer is still the main cause of death and has caused serious social and economic distress on a global scale over the past few decades. In low and middle-income countries, the incidence of cancer has risen sharply \[[@R2]\]. To date, there are a few identified risk factors for acute pancreatitis, including smoking, infection, occupational exposure, environmental pollution, unreasonable diet and genetic factors. Previous studies indicated that tooth loss may be a risk factors in cancer, but presented controversial results.

In the current meta-analysis was based on 25 case-control or cohort study, with more than 1.3 million participants and 32925 cases from eleven countries. Thus, this meta analysis provides the most up-to-date epidemiological evidence supporting tooth loss is harmful for cancer. A dose-response analysis revealed that a per 10 of tooth loss increase was associated with a 9% increment of cancer risk, 14% increment of esophageal cancer risk, 9% increment of gastric cancer risk, 31% increment of head and neck cancer risk, 4% increment of colorectal cancer risk, 7% increment of pancreas cancer risk, 19% increment of lung cancer risk, 3% increment of prostate cancer risk, 2% increment of bladder cancer risk and 3% increment of hematopoietic cancer risk. Subgroup meta-analyses by various factors also showed consistent findings.

Several plausible pathways may reasonable for the relationship between tooth loss and cancer. The influence of chronic inflammation on cancer development is one possible pathway. Chronic systemic inflammation linked to periodontal disease \[[@R36], [@R37]\], which is a major cause of tooth loss in adults that can increase the risk of cancer by inhibiting apoptosis and stimulating tumor cell proliferation \[[@R38]\]. Secondly, the main cause of teeth loss is dental caries \[[@R39], [@R40]\], and carbohydrate intake is the dental caries cause. Carbohydrate intake was associated with increased risk cancer \[[@R41], [@R42]\]. Third, the progress of tooth damage destroys normal periodontal tissue, allowing oral microbial accumulation deep into oral tissue, thereby promoting its growth \[[@R43]\]. Thus, tooth loss and cancer seems to be closely related.

To our knowledge, this is the first study to identify and quantify the potential dose-response association between tooth loss and cancer risk in a large cohort of both men and women. Although, we performed this meta-analysis very carefully, however, some limitations must be considered in the current meta-analysis. First, different sex of population should be included in this meta-analysis to explore the impact of different sex of population on tooth loss and cancer risk. Second, we only select literature that written by English, which may have resulted in a language or cultural bias, other language should be chosen in the further. Third, in the subgroup analysis in cancer type, there might be insufficient statistical power to check an association. Fourth, Though some data were obtained from retrospective studies, most of retrospective studies only to identify the relationship between tooth loss and cancer risk, and we also add more study to identify and quantify the potential dose-response association between tooth loss and cancer risk.

In conclusion, our findings underscore the notion that tooth loss was associated with cancer risk increment. In the future, large-scale and population based association studies must be performed in the future to validate the risk identified in the current meta-analysis.
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